 Rutherford, N.J., Oct. 28, 2020 GLOBE NEWSWIRE -- Cancer Genetics, Inc. Nasdaq: CGIX Cancer Genetics, a leader in in drug discovery and preclinical oncology and immuno-oncology services, announced today that it has entered into an underwriting agreement with H.C. Wainwright Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 909,091 shares of common stock of the Company at a price to the public of 2.20 per share, less underwriting discounts and commissions. The offering is expected to close on or about November 2, 2020, subject to satisfaction of customary closing conditions. 